Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New antilipemics: prospects].

Michel Farnier1

  • 1mfarnier@ipac.fr

Therapie
|June 26, 2003
PubMed
Summary
This summary is machine-generated.

Researchers are developing new, safer lipid-lowering drugs, including advanced statins and novel drug classes like cholesterol absorption inhibitors. Combination therapies, such as statin-ezetimibe, are being explored for various lipid disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins.

Frontiers in cardiovascular medicine·2026
Same author

Dosage of lipoproteins for risk management according to guidelines.

Vascular diseases (Paris, France)·2026
Same author

Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINI.

Frontiers in cardiovascular medicine·2026
Same author

Not all fibrates are made equal: Learning from biology and clinical trials.

Atherosclerosis·2025
Same author

Higher EPA levels and EPA/DHA Ratios Are associated with Lower Cardiovascular Mortality Post-Myocardial Infarction.

European journal of preventive cardiology·2025
Same author

Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France.

Archives of cardiovascular diseases·2025

Area of Science:

  • Pharmacology
  • Medicinal Chemistry

Context:

  • Active research in novel lipid-lowering drugs aims for enhanced efficacy and safety.
  • Development focuses on improving existing statins and introducing new drug classes.

Purpose:

  • To review current advancements in lipid-lowering drug research.
  • To highlight promising new drug classes and combination therapies for dyslipidemia.

Summary:

  • Statins like rosuvastatin and pitavastatin are advanced. New classes include cholesterol absorption inhibitors (ezetimibe) and PPAR activators.
  • Other investigated drugs include ACAT, MTP, CETP, and ileal bile acid transporter inhibitors.
  • Combination therapies, particularly with statins, are tailored to specific lipid abnormalities, with statin-ezetimibe and statin-bile acid sequestrant combinations studied for hypercholesterolemia.

Related Experiment Videos

Impact:

  • Combination therapies like statin-ezetimibe and statin-PPAR activators show promise for hypercholesterolemia, combined hyperlipidemia, and type 2 diabetes.
  • Further research is needed for ACAT and CETP inhibitors; MTP inhibitors face development hurdles.
  • Discovery of new lipoprotein receptors (ABCA1, SRB1) offers novel targets for future drug development.